Single-cell landscape of immunological responses in patients with COVID-19
…, Z Xu, C Zhang, JW Song, X Fan, P Xia, JL Fu… - Nature …, 2020 - nature.com
In coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host …
coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host …
[PDF][PDF] Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis
…, H Tian, GH Chua, C Zhang, FP Meng, Z Xu, JL Fu… - Cell metabolism, 2020 - cell.com
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented threat to
global public health. Herein, we utilized a combination of targeted and untargeted tandem …
global public health. Herein, we utilized a combination of targeted and untargeted tandem …
[PDF][PDF] Interleukin‐17–producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B
Interleukin‐17 (IL‐17)‐producing CD4 + T cells (Th17)‐mediated immune response has been
demonstrated to play a critical role in inflammation‐associated disease; however, its role …
demonstrated to play a critical role in inflammation‐associated disease; however, its role …
PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors
JY Zhang, Z Zhang, X Wang, JL Fu… - Blood, The Journal …, 2007 - ashpublications.org
The immunoreceptor PD-1 is significantly up-regulated on exhausted CD8 + T cells during
chronic viral infections such as HIV-1. However, it remains unknown whether PD-1 …
chronic viral infections such as HIV-1. However, it remains unknown whether PD-1 …
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase …
…, C Zhang, X Yuan, Z Xu, L Huang, JL Fu… - Signal transduction and …, 2021 - nature.com
Abstract Treatment of severe Coronavirus Disease 2019 (COVID-19) is challenging. We
performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-…
performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-…
Hyper-Activated Pro-Inflammatory CD16+ Monocytes Correlate with the Severity of Liver Injury and Fibrosis in Patients with Chronic Hepatitis B
JY Zhang, ZS Zou, A Huang, Z Zhang, JL Fu, XS Xu… - PloS one, 2011 - journals.plos.org
Background Extensive mononuclear cell infiltration is strongly correlated with liver damage
in patients with chronic hepatitis B virus (CHB) infection. Macrophages and infiltrating …
in patients with chronic hepatitis B virus (CHB) infection. Macrophages and infiltrating …
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial
M Shi, YY Li, RN Xu, FP Meng, SJ Yu, JL Fu… - Hepatology …, 2021 - Springer
Background Mesenchymal stem cell (MSC) infusion was reported to improve liver function
in patients with decompensated liver cirrhosis (DLC); however, whether the medication can …
in patients with decompensated liver cirrhosis (DLC); however, whether the medication can …
Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure
BACKGROUND/AIMS: Functionally impaired dendritic cells (DCs) play important roles in
suppressing host immune responses and facilitating viral persistence in chronic hepatitis B …
suppressing host immune responses and facilitating viral persistence in chronic hepatitis B …
Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment
Background Treatment with nucleotide analogs is known to be effective in inhibiting HBV
replication; however, patients with chronic hepatitis B (CHB) often show a wide range of clinical …
replication; however, patients with chronic hepatitis B (CHB) often show a wide range of clinical …
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
…, C Zhang, B Zhang, J Song, L Huang, Z Xu, JL Fu… - …, 2022 - thelancet.com
Background The long-term consequences of human umbilical cord-derived mesenchymal
stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study …
stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study …
